April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
C02 Laser Assisted Sclerectomy Surgery (CLASS)- A Novel Filtration Procedure For Glaucoma Treatment
Author Affiliations & Notes
  • Noa Geffen
    Ophthalmology, Meir Medical Center, Kfar-Saba, Israel
  • Yokrat Ton
    Ophthalmology, Meir Medical Center, Kfar-Saba, Israel
  • Ehud I. Assia
    Ophthalmology, Meir Medical Center, Kfar-Saba, Israel
  • Footnotes
    Commercial Relationships  Noa Geffen, IOPtima, Ltd (C); Yokrat Ton, None; Ehud I. Assia, Inventor designated on a patent which is the subject of presentation (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2628. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Noa Geffen, Yokrat Ton, Ehud I. Assia; C02 Laser Assisted Sclerectomy Surgery (CLASS)- A Novel Filtration Procedure For Glaucoma Treatment. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2628.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of CO2 Laser Assisted Sclerectomy Surgery (CLASS) in primary and pseudoexfoliative open-angle glaucoma (OAG).

Methods: : A prospective, multi-center, multi-national clinical study. Candidates for primary filtration surgery underwent CLASS with a CO2 laser system (OT-134-"IOPtiMate", IOPtima Ltd., Ramat Gan, Israel). The system gradually ablates and removes scleral layers until percolating fluid absorbs the energy, attenuating further tissue ablation. Intraocular pressure (IOP) was measured at baseline, 1, 2, 4 and 6 weeks, and 3, 6, 12 and 24 months. Complete success was defined as 5≤ IOP≤ 18 mmHg and 20% IOP reduction with no medications, and qualified success as the same IOP range with or without medications.

Results: : 62 subjects with OAG underwent the procedure in 5 sites. 47 and 16 completed 12 and 24 months of follow-up by the time of writing this abstract. Mitomycin C was used in 50 procedures (80.6%). The mean baseline IOP of 25.2 ± 6.01 mmHg (mean ±SD) dropped to 13.4 ± 3.32 and 14.6 ± 2.83 mmHg at 12 and 24 months, respectively, with 47.5 % and 42.7 % reduction at 12 and 24 months, respectively (P<0.001). Complete success was achieved by 71.1% and 62.5% of the subjects at 12 and 24 months, respectively, whereas qualified success was achieved by 88.8% and 81.2%. Average number of medications dropped from 2.0 to 0.25 at 24 months. Complications were mild and transitory with no sequela.

Conclusions: : Short and intermediate term results suggest that CLASS may become simple, safe and effective means of choice for OAG treatment.

Clinical Trial: : NIH, NA

Keywords: laser • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×